Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography

Martin Bauer1, Akihiro Matsuda1, Beatrix Wulkersdorfer1, Cécile Philippe2, Alexander Traxl3, Csilla Özvegy-Laczka4, Johann Stanek1,3, Lukas Nics2, Eva-Maria Klebermass2, Stefan Poschner5, Walter Jäger5, Izabel Patik4, Éva Bakos4, Gergely Szakács4,6, Wolfgang Wadsak2,7, Marcus Hacker2, Markus Zeitlinger1 and Oliver Langer1,2,3

To assess the hepatic disposition of erlotinib, we performed positron emission tomography (PET) scans with $^{[11]}$C-erlotinib in healthy volunteers without and with oral pretreatment with a therapeutic erlotinib dose (300 mg). Erlotinib pretreatment significantly decreased the liver exposure to $^{[11]}$C-erlotinib with a concomitant increase in blood exposure, pointing to the involvement of a carrier-mediated hepatic uptake mechanism. Using cell lines overexpressing human organic anion-transporting polypeptides (OATPs) 1B1, 1B3, or 2B1, we show that $^{[11]}$C-erlotinib is selectively transported by OATP2B1. Our data suggest that at PET microdoses hepatic uptake of $^{[11]}$C-erlotinib is mediated by OATP2B1, whereas at therapeutic doses OATP2B1 transport is saturated and hepatic uptake occurs mainly by passive diffusion. We propose that $^{[11]}$C-erlotinib may be used as a hepatic OATP2B1 probe substrate and erlotinib as an OATP2B1 inhibitor in clinical drug–drug interaction studies, allowing the contribution of OATP2B1 to the hepatic uptake of drugs to be revealed.

Study Highlights

**WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?**
☐ OATP2B1 is expressed in the sinusoidal membrane of hepatocytes, where it may mediate uptake of drugs from blood into liver, but its contribution to hepatic drug disposition has remained elusive due to a lack of OATP2B1-specific probe substrates and inhibitors.

**WHAT QUESTION DID THIS STUDY ADDRESS?**
☐ We performed PET imaging with the radiolabeled tyrosine kinase inhibitor $^{[11]}$C-erlotinib and *in vitro* transport experiments to study hepatic disposition of erlotinib in humans.

**WHAT THIS STUDY ADDS TO OUR KNOWLEDGE**
☐ Our data suggest that $^{[11]}$C-erlotinib is taken up into the liver at PET microdoses by OATP2B1 without being transported by OATP1B1 and OATP1B3. Moreover, pretreatment of subjects with a therapeutic dose of erlotinib appeared to saturate OATP2B1-mediated uptake of $^{[11]}$C-erlotinib into the liver with a concomitant increase in blood exposure.

**HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE**
☐ Erlotinib may be used as an OATP2B1 inhibitor in clinical drug–drug interaction studies, allowing the contribution of OATP2B1 to the hepatic uptake of drugs to be revealed.

The liver is a major clearance organ for many drugs. There is an interplay between transporters expressed in the blood-facing sinusoidal and bile-facing canalicular membranes of hepatocytes and intracellular metabolizing enzymes in the hepatobiliary clearance of drugs.1 Uptake of drugs from blood into hepatocytes is often mediated by uptake transporters belonging to the solute carrier (SLC) family, such as organic anion-transporting polypeptides (OATPs), whereas efflux of drugs and drug metabolites into bile is mediated by canalicular efflux transporters belonging to the adenosine triphosphate-binding cassette (ABC) family, such as multidrug resistance-associated protein 2 (MRP2/ABCC2). Hepatic transporters are of great relevance in clinical pharmacology, as their altered activity due to drug–drug interactions (DDIs), genetic polymorphisms, or disease may lead to pronounced changes in blood and liver exposure to drugs, which may severely impact drug safety or efficacy.2–6 In clinical studies, alterations in the activity of hepatic transporters are usually assessed by studying drug plasma pharmacokinetics. However, to better understand the impact of hepatic transporters on drug disposition, a direct assessment of drug kinetics in the liver is...
Erlotinib is a tyrosine kinase inhibitor (TKI) used for the treatment of nonsmall-cell lung cancer. It is predominantly excreted in the hepatobiliary route and has been identified as a substrate of nonsmall-cell lung cancer. It is predominantly excreted via the hepatobiliary route and has been identified as a substrate of multidrug resistance protein 1 (P-glycoprotein (Pgp/ABCB1), organic anion transporter 3 (OAT3/SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2)). It is currently not known whether hepatic SLC and ABC transporters, the specific contribution of individual transporters cannot be distinguished.

Erlotinib is a tyrosine kinase inhibitor (TKI) used for the treatment of nonsmall-cell lung cancer. It is predominantly excreted via the hepatobiliary route and has been identified as a substrate of breast cancer resistance protein (BCRP/ABCG2), P-glycoprotein (Pgp/ABCB1), organic anion transporter 3 (OAT3/SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2)). It is currently not known whether hepatic uptake of erlotinib occurs via a transporter-mediated mechanism or passive diffusion. In a preclinical PET study in mice, we observed that the rate constant for hepatic uptake of [11C]erlotinib was markedly (~2-fold) reduced in animals coinfected with a pharmacological dose of erlotinib (10 mg/kg) as compared with animals that only received a PET microdose of erlotinib, with a concomitant increase in blood exposure.

In this study we assessed the hepatic disposition of erlotinib in healthy human volunteers by performing [11C]erlotinib PET scans without and with oral pretreatment with a therapeutic dose of erlotinib. Data were analyzed using pharmacokinetic modeling and complemented by in vitro experiments examining transport of [11C]erlotinib by different OATPs expressed in the human liver.

RESULTS

PET study
Study participants underwent two PET scans with [11C]erlotinib: a first baseline scan in which a microdose of erlotinib was administered (<10 μg), and a second scan which was performed 3h after the oral intake of erlotinib at a dose of 300 mg, corresponding to twice a standard therapeutic dose. The study medication was well tolerated by all subjects with no occurrence of adverse events.

The percentage of radiolabeled metabolites of [11C]erlotinib was <10% of total radioactivity in plasma in both PET scans and at all studied timepoints. Plasma protein binding of [11C]erlotinib was not significantly different between scan 1 and scan 2 (scan 1: 96.9 ± 1.8%, scan 2: 95.8 ± 1.4%, n = 4). Pharmacokinetic parameters of unlabeled erlotinib in plasma are summarized in Supplementary Table 1. Maximum plasma concentration (C_max) after oral intake was achieved at a median of 5 h (range 2–6 h) with a mean value of 4.6 ± 1.3 μM. Erlotinib plasma concentration at the time of the PET scan (mean of values at 3 h and 4 h after oral intake) was 4.2 ± 1.0 μM, corresponding to an unbound concentration of 0.18 μM.

In Figure 1, representative PET images of the abdominal region are shown, indicating rapid and high radioactivity uptake in the liver and high uptake in bile duct and gall bladder at later timepoints. In scan 2, radioactivity uptake in liver, bile duct, and gall bladder was markedly reduced as compared with scan 1. In Figure 2, time–activity curves are shown for both scans. In scan 2, area under the curve (AUC) of [11C]erlotinib in blood was significantly increased as compared with scan 1 (scan 1: 0.091 ± 0.014 percent of the injected dose (%ID)/mL·min, scan 2: 0.170 ± 0.021 %ID/mL·min, change in scan 2: +90 ± 23%). Accordingly, total clearance of [11C]erlotinib was significantly decreased in scan 2 (scan 1: 46 ± 10 L/h, scan 2: 10 ± 4 L/h, −77 ± 14%). While the initial uptake kinetics of radioactivity into the liver were similar in scan 1 and scan 2, the liver curves diverged at later timepoints (>4 min) in the two scans. Radioactivity continued to accumulate over time in scan 1, whereas radioactivity washed out from the liver following maximum uptake in scan 2 (Figure 2b). The total liver exposure to radioactivity was significantly lower in scan 2 (liver AUC scan 1: 1.511 ± 0.294 %ID/mL·min, scan 2: 0.652 ± 0.096 %ID/mL·min, −56 ± 5%) and liver-to-blood AUC ratios of radioactivity were significantly decreased (AUC liver/AUC blood = 0.294 %ID/mL·min, scan 2: 0.652 ± 0.096 %ID/mL·min, −56 ± 5%).}

**Figure 1** Representative PET images (subject 4) of the abdominal region for baseline scan (scan 1) and scan after oral intake of erlotinib (scan 2) recorded at 3.5, 17.5, 42.5, 67.5, and 87.5 min after radiotracer injection. Radioactivity concentration is expressed as percent of the injected dose per mL (%ID/mL) and radiation scale is set from 0 to 0.04. Anatomical structures are labeled with arrows (L, liver; GB, gall bladder; BD, bile duct; C, colon; S, spleen).
Also, liver-to-blood concentration ratios ($K_{b,liver}$) were markedly lower in scan 2 (Figure 2d). During the time course of the PET scan radioactivity was excreted into the bile duct and gall bladder, whereby the excreted radioactivity amount was significantly lower in scan 2 (bile duct and gall bladder AUC scan 1: 364 ± 61 %ID*min, scan 2: 121 ± 67 %ID*min, −69 ± 12%) (Supplementary Figure 1a). In contrast to the liver, the radioactivity concentration in the kidneys was very low and not significantly different between the two scans (Supplementary Figure 1b).

PET data were analyzed using pharmacokinetic modeling to estimate the influx rate constant from blood into liver ($k_{influx}$), hepatic uptake clearance ($CL_{uptake}$), the backflux rate constant from liver into blood ($k_{backflux}$), and the rate constants for biliary excretion ($k_{bile}$) and for elimination of [11C]erlotinib from blood ($k_{el}$) (Figure 3). In addition, the apparent [11C]erlotinib influx into the liver at steady state ($k_{influx}/k_{backflux}$) was calculated. The model did not provide physiologically meaningful results for Subject 5, in that $CL_{uptake}$ greatly exceeded the liver blood flow, so that this subject was excluded from the modeling analysis. Fitted curves for one representative subject are shown in Supplementary Figure 2.

In Table 1, modeling outcome parameters are given for five subjects and in Figure 4 changes in outcome parameters are depicted for individual subjects. In scan 2, $k_{backflux}$ was significantly increased (scan 1: 0.035 ± 0.016 min$^{-1}$, scan 2: 0.160 ± 0.025 min$^{-1}$, + 345 ± 232%) and $k_{influx}/k_{backflux}$ was significantly decreased (scan 1: 24.7 ± 9.5, scan 2: 4.4 ± 1.4, −80 ± 9%). In addition, there was a trend for decreases in $k_{influx}$, $CL_{uptake}$, $k_{bile}$, and $k_{el}$ in scan 2 ($k_{influx}$ scan 1: 0.74 ± 0.11 min$^{-1}$, scan 2: 0.70 ± 0.28 min$^{-1}$; $CL_{uptake}$ scan 1: 1,687 ± 397 mL min$^{-1}$, scan 2: 1,532 ± 478 mL min$^{-1}$; $k_{bile}$ scan 1: 0.0030 ± 0.0012 min$^{-1}$, scan 2: 0.0023 ± 0.0018 min$^{-1}$; $k_{el}$ scan 1:
Table 1. Outcome parameters from liver model for baseline scan and scan after oral intake of erlotinib in individual subjects

| Subject | Baseline | After oral erlotinib |
|---------|----------|---------------------|
|         | \(k_{influx}\) | \(k_{influx}\) |
|         | \(\text{min}^{-1}\) | \(\text{min}^{-1}\) |
| 1       | 0.031 ± 0.014 | 0.031 ± 0.014 |
| 2       | 0.036 ± 0.011 | 0.036 ± 0.011 |
| 3       | 0.039 ± 0.012 | 0.039 ± 0.012 |
| 4       | 0.060 ± 0.013 | 0.060 ± 0.013 |
| 5       | 0.069 ± 0.014 | 0.069 ± 0.014 |

\(k_{influx}\) is the influx rate constant from blood into liver, \(k_{backflux}\) is the backflux rate constant from liver into blood, and \(k_{bile}\) is the rate constant for biliary excretion.

Parameter estimates are given as mean ± standard deviation.

\(CL_{uptake}\) is the hepatic uptake clearance. \(CL_{uptake}\) was calculated by multiplying \(k_{influx}\) with the volume of distribution \(V_d\).

\(K_{IC50}\) is the Michaelis constant. \(K_{IC50}\) values for OCT1 (SLC22A1) and OAT2 (SLC22A7) were not reported as the methods did not provide physiologically meaningful results. Calculated by multiplying \(k_{influx}\) with volume of distribution \(V_d\).

\(K_{IC50}\) is the Michaelis constant for \([11C]erlotinib\) and found a pronounced decrease in liver uptake when subjects were pretreated with an oral therapeutic dose of erlotinib. This pointed to the involvement of a carrier-mediated hepatic uptake mechanism of erlotinib. Although erlotinib is a frequently used drug, the mechanism of its liver uptake has not yet been identified. Erlotinib was found not to be transported by the major hepatic uptake transporters OATP1B1 and OATP1B3. In addition, it has been shown that erlotinib is not a substrate of OCT1 (SLC22A1) and OAT2 (SLC22A7), two other uptake transporters expressed in hepatocytes. Erlotinib was found to be a very potent inhibitor of OATP2B1. Johnston et al. reported a half-maximum inhibitory concentration \((IC_{50}\) of 0.03 \(\mu M\) of erlotinib for OATP2B1 inhibition and a 3.467- and 40-fold lower potency for inhibition of OATP1B1 \((IC_{50}\) of 104 \(\mu M\)) and OATP1B3 \((IC_{50}\) of 1.19 \(\mu M\)), respectively. It was suggested that erlotinib is a competitive inhibitor of OATP2B1, but its transport by OATP2B1 has not been directly assessed so far. Sato et al. found that the structurally related TKI gefitinib was transported by OATP2B1. We hypothesized that the reduction in \([11C]erlotinib\) liver uptake observed in our study following pretreatment with erlotinib may be due to saturation of \([11C]erlotinib\) transport by OATP2B1. We performed in vitro uptake experiments with tracer

In vitro uptake experiments

To investigate if \([11C]erlotinib\) is a substrate of OATPs expressed in the liver, we performed in vitro uptake experiments using tracer concentrations (<0.1 \(\mu M\)) of \([11C]erlotinib\) in A431 cells engineered to stably overexpress OATP1B1 (SLCO1B1), OATP1B3 (SLCO1B3), or OATP2B1 (SLCO2B1) (Figure 5). After 5 min incubation time at pH 7.4, uptake of \([11C]erlotinib\) was not significantly different between cells transfected with the empty vector and cells overexpressing OATP1B1 or OATP1B3. In contrast, in OATP2B1 overexpressing cells, \([11C]erlotinib\) uptake was significantly higher (+22%). We incubated cells with \([11C]erlotinib\) in the presence of an excess of unlabeled erlotinib (1 \(\mu M\)) or the prototypical OATP inhibitors cyclosporine A (10 \(\mu M\)) or rifampicin (100 \(\mu M\)). All three compounds significantly decreased \([11C]erlotinib\) uptake in OATP2B1 overexpressing cells to comparable levels as in vector control cells, while the same treatment had no effect in OATP1B1 and OATP1B3 overexpressing cells (Figure 5a). We also assessed the time dependency of \([11C]erlotinib\) uptake into OATP-overexpressing and vector control cells, which indicated higher uptake of \([11C]erlotinib\) in OATP2B1 overexpressing cells as compared with the other cells, with a maximum difference reached after 10–15 min of incubation time (Figure 5b). Kinetic analysis revealed both a saturable and nonsaturable component for OATP2B1-specific uptake of \([11C]erlotinib\) (Figure 5c). The Michaelis constant \((K_m)\) of the saturable component was 0.324 ± 0.182 \(\mu M\).

DISCUSSION

In this study we used PET imaging to assess hepatic disposition of \([11C]erlotinib\) and found a pronounced decrease in liver uptake when subjects were pretreated with an oral therapeutic dose of erlotinib. This pointed to the involvement of a carrier-mediated hepatic uptake mechanism of erlotinib. Although erlotinib is a frequently used drug, the mechanism of its liver uptake has not yet been identified. Erlotinib was found not to be transported by the major hepatic uptake transporters OATP1B1 and OATP1B3. In addition, it has been shown that erlotinib is not a substrate of OCT1 (SLC22A1) and OAT2 (SLC22A7), two other uptake transporters expressed in hepatocytes. Erlotinib was found to be a very potent inhibitor of OATP2B1. Johnston et al. reported a half-maximum inhibitory concentration \((IC_{50}\) of 0.03 \(\mu M\) of erlotinib for OATP2B1 inhibition and a 3.467- and 40-fold lower potency for inhibition of OATP1B1 \((IC_{50}\) of 104 \(\mu M\)) and OATP1B3 \((IC_{50}\) of 1.19 \(\mu M\)), respectively. It was suggested that erlotinib is a competitive inhibitor of OATP2B1, but its transport by OATP2B1 has not been directly assessed so far. Sato et al. found that the structurally related TKI gefitinib was transported by OATP2B1. We hypothesized that the reduction in \([11C]erlotinib\) liver uptake observed in our study following pretreatment with erlotinib may be due to saturation of \([11C]erlotinib\) transport by OATP2B1. We performed in vitro uptake experiments with tracer
concentrations (<0.1 μM) of [11C]erlotinib in cell lines overexpressing different OATP isoforms (Figure 5a). We found a significantly higher uptake of [11C]erlotinib as compared to control cells in OATP2B1 overexpressing cells, and a reduction in cellular uptake when unlabeled erlotinib or the prototypical OATP inhibitors cyclosporine A or rifampicin were added. Kinetic experiments indicated that OATP2B1 is a high-affinity and low-capacity transporter of erlotinib (Figure 5c). Our data confirm the findings by Khurana et al. that erlotinib is not transported by OATP1B1 and 3B3.21 For the first time, we show that erlotinib at low concentrations is transported by OATP2B1 and that transport is saturated at therapeutic erlotinib concentrations.

In vivo, [11C]erlotinib was rapidly taken up into the liver after intravenous (i.v.) injection followed by sustained liver uptake for the duration of the PET scan. Oral pretreatment with erlotinib markedly reduced liver uptake of [11C]erlotinib with a concomitant decrease in total clearance of [11C]erlotinib. This dose dependency in [11C]erlotinib clearance is in good agreement with a dose escalation study of i.v. erlotinib in cancer patients, in whom a decrease in clearance was observed with increasing erlotinib dose.25 The mean unbound plasma concentration of unlabeled erlotinib at the time of the PET scan (0.18 μM) was in a similar range as the in vitro \( K_m \) value for erlotinib transport by OATP2B1 (0.32 μM). As there is evidence that portal blood concentrations of drugs after oral dosing may be several times higher than peripheral blood concentrations,26 it appears possible that the reduced liver distribution of [11C]erlotinib after oral erlotinib was caused by saturation of OATP2B1-mediated liver uptake of [11C]erlotinib.

PET data were analyzed using a pharmacokinetic model (Figure 3), yielding \( k_{\text{influx}} \), \( CL_{\text{uptake}} \), \( k_{\text{backflux}} \), and \( k_{\text{bile}} \) as outcome parameters for the liver. In scan 1, \( CL_{\text{uptake}} \) was 21 ± 4 mL min\(^{-1}\) kg\(^{-1}\), which was close to the hepatic blood flow (21 mL min\(^{-1}\) kg\(^{-1}\)), and therefore corresponded to a hepatic extraction ratio close to 1. Contrary to what would be expected from the inhibition of an uptake transporter11,12,14 and contrary to our preclinical results,20 \( CL_{\text{uptake}} \) was only moderately reduced in some subjects in scan 2 (Figure 4a). The liver time–activity curves showed very similar initial hepatic uptake kinetics in the two PET scans (Figure 2b). This agrees quite well with the in vitro uptake kinetics (Figure 5b), in which the maximum difference between OATP2B1-overexpressing and vector control cells was reached at later timepoints. [11C]Erlotinib rapidly washed out from the liver in scan 2 at timepoints >4 min, whereas it continued to accumulate in the liver in scan 1 (Figure 2b). This behavior was reflected by a pronounced increase (+435%) in \( k_{\text{backflux}} \) in scan 2 (Figure 4b), which may have masked a decrease in \( CL_{\text{uptake}} \). Interestingly, a similar phenomenon has been observed in a study by Pfeifer et al., who assessed the effect of the OATP inhibitor ritonavir on liver distribution of the single-photon emission computed tomography (SPECT) tracer [99mTc]mebrofenin, which is a substrate of OATP1B1, OATP1B3, MRP2, and MRP3.28 Those authors reported a 46% reduction in \( CL_{\text{uptake}} \) and a 517% increase in the efflux clearance of [99mTc]mebrofenin from liver to blood following ritonavir.
have displaced protein binding of \([^{11}C]\)erlotinib in the liver, leading to an increase in the hepatic unbound fraction, which could have driven passive back-diffusion of \([^{11}C]\)erlotinib across the basolateral membrane from liver into blood. Saturation of OATP2B1 by unlabeled erlotinib may have prevented OATP2B1-mediated reuptake of \([^{11}C]\)erlotinib from blood into liver, which may have contributed to the increase in \(k_{\text{backflux}}\). This is supported by a significant positive correlation between the percent change in \(k_{\text{backflux}}\) in scan 2 and the plasma AUC of unlabeled erlotinib from time zero to the end of the PET scan (Spearman correlation coefficient \(r = 1.00, P = 0.017\), data not shown). This hypothesis remains to be proven in future experiments. It is noteworthy that in another clinical PET study, which assessed the effect of a hepatic uptake transporter (OCT1) on liver distribution of a drug ([\(^{11}\)C]metformin), also an increase in \(k_{\text{backflux}}\) was found under conditions when uptake transport was impaired (i.e., in carriers of genetic \(SLC22A1\) polymorphisms).

To reflect changes in both \(k_{\text{influx}}\) and \(k_{\text{backflux}}\) in scan 2, we calculated \(k_{\text{influx}}/k_{\text{backflux}}\) as the apparent \([^{11}C]\)erlotinib influx into the liver at steady state, which was significantly decreased (by 80%) in scan 2 (Figure 4c). Our assumption that liver uptake in scan 2 occurs by passive diffusion is supported by the observation that liver and blood time–activity curves were parallel in scan 2, which was not the case in scan 1 (Supplementary Figure 3). The rate constant for transport of \([^{11}C]\)erlotinib from hepatocytes into bile, \(k_{\text{bile}}\), was reduced in three out of five subjects following pretreatment with erlotinib (Figure 4d). This is in good agreement with our preclinical data in mice, which showed a 5-fold reduction in \(k_{\text{bile}}\) of \([^{11}C]\)erlotinib when unlabeled erlotinib was co-injected, presumably due to saturation of Bcrp and Pgp transport.

The liver receives dual blood supply via the hepatic artery (\(\sim\)25%) and via the portal vein (\(\sim\)75%). Blood from the portal vein cannot be sampled in humans, and our attempts to generate an image-derived portal input function were unsuccessful. We therefore did not consider tracer delivery via the portal vein in our pharmacokinetic model, which may have led to an underestimation of modeling outcome parameters but should not have affected relative changes in outcome parameters between scans.

Over the time course of the PET scan \([^{11}C]\)erlotinib may also undergo direct intestinal secretion from blood, as reflected by delayed radioactivity uptake in the colon (Figure 1). This process may be transporter-mediated, because a decrease in the concentration of radioactivity secreted into colon was observed after pretreatment with erlotinib (Supplementary Figure 1a). A compartment for intestinal excretion of radiotracer was not included in our pharmacokinetic model, as only a small colon segment was within the field of view of the PET scanner and we were not able to determine the total amount of radioactivity excreted into the intestine. Renal uptake of \([^{11}C]\)erlotinib was negligible, which is in accordance with low renal excretion of erlotinib.\(^{17}\) Erlotinib is predominately excreted in the form of metabolites into feces, whereas in plasma unchanged erlotinib represents the major circulating compound.\(^{17}\) In agreement with literature data, we found only a low amount of radiolabeled metabolites of \([^{11}C]\)erlotinib in plasma. In an earlier study in mice, we measured the content of radiolabeled metabolites of
We found that the majority of radioactivity in plasma, liver, and bile was in the form of unchanged \(^{11}\text{C}\)erlotinib, suggesting that metabolism of \(^{11}\text{C}\)erlotinib may not be as important over the short duration of a PET scan.

OATP-mediated DDIs are of great concern in drug development, and current guidelines by the European Medicines Agency and the US Food and Drug Administration recommend in vitro studies to assess the interaction of new drug candidates with OATP1B1 and OATP1B3. In selected cases in which an OATP-mediated DDI risk cannot be excluded, clinical studies employing prototypical OATP inhibitors (e.g., rifampicin or cyclosporine A) or nonselective OATP probe substrates (e.g., rosuvastatin, pravastatin, pitavastatin) are recommended. Whereas the role of OATP1B1 and 1B3 in hepatic uptake of drugs is firmly established, the contribution of OATP2B1 to hepatic drug disposition has so far remained elusive. This may be related to the fact that most drugs that show affinity for OATP2B1 are also transported by OATP1B1 and/or 1B3 and that OATP2B1-selective inhibitors for in vivo use are not available. Although certain drugs inhibit OATP2B1 (e.g., gemfibrozil, cyclosporine A), clinically relevant DDIs that can be specifically attributed to hepatic OATP2B1 have not yet been reported.

Our data suggest that erlotinib is taken up into the human liver at PET microdoses both by OATP2B1 and by passive diffusion, whereas at therapeutic doses erlotinib transport by OATP2B1 is saturated so that liver uptake occurs mainly by passive diffusion. We propose that \(^{11}\text{C}\)erlotinib may be used as a hepatic OATP2B1 probe substrate and erlotinib as an OATP2B1 inhibitor in clinical liver DDI studies. OATP2B1 inhibition with erlotinib may help reveal the contribution of OATP2B1 to the hepatic uptake of drugs which are transported by several OATPs expressed in the liver. On the other hand, caution is warranted when combining erlotinib with OATP2B1 substrates (e.g., statins) in the clinic, as this may lead to clinically relevant DDIs due to OATP2B1 inhibition in the liver and rises in blood concentrations of victim drugs. One study evaluated the antitumor activity of a combination of erlotinib with the OATP2B1 substrate rosuvastatin in 24 patients with advanced solid malignancies. In this study, muscle toxicity was observed at a substantially higher rate (34%) than during standard statin therapy (1–5%), with seven cases of myalgia and one case of rhabdomyolysis resulting in a study-related death. Muscle toxicity of rosuvastatin may have been caused by inhibition of OATP2B1-mediated hepatic rosuvastatin uptake by erlotinib, leading to increases in rosuvastatin blood exposure.

In conclusion, despite the fact that previous studies have indicated that erlotinib interacts with multiple SLC and ABC transporters, our data suggest that PET with \(^{11}\text{C}\)erlotinib can measure OATP2B1 transport activity in the human liver, suggesting a potential utility as a hepatic OATP2B1 probe substrate for in vivo DDI studies. Unexpectedly, uptake transporter inhibition was mainly associated with an increase in \(k_{\text{back}}\) rather than a decrease in \(CL_{\text{uptake}}\) in our pharmacokinetic model. As the contribution of OATP2B1 to the liver uptake of \(^{11}\text{C}\)erlotinib appeared to be quite small, an OATP2B1-specific probe substrate with lower passive permeability than erlotinib may be preferable for future studies. Our study is a unique example of a drug which shows transporter-mediated liver uptake at PET microdoses but not at therapeutic doses, leading to nonlinear pharmacokinetics.

**METHODS**

The study was registered under EUDRACT number 2015-001593-18, approved by the Ethics Committee of the Medical University of Vienna and conducted in accordance with the Declaration of Helsinki and its amendments. Written consent was obtained from all subjects. Study participants were defined as healthy based on medical history, physical examination, and routine blood and urine laboratory testing. Further, subjects were required to be free of any medication for at least 14 days before start of the study, which was confirmed by a urine drug screen.

**Radiotracer synthesis**

\(^{11}\text{C}\)Erlotinib was synthesized following a previously published procedure and formulated in sterile phosphate-buffered saline solution containing 8.6% (v/v) ethanol. Molar radioactivity at the time of injection was 61 ± 51 GBq/μmol (n = 12 batches) and radiochemical purity was >98%.

**Imaging and sampling**

One female and five male healthy volunteers (mean age: 27 ± 6 years, mean weight: 79 ± 7 kg) were enrolled in the study. All subjects underwent magnetic resonance imaging (MRI) of the upper abdomen (T1- and T2-weighted MAGNETOM Skyra 3.0T MRI, Siemens Medical Solutions, Erlangen, Germany) and two dynamic \(^{11}\text{C}\)erlotinib PET scans conducted on separate days on an Advance scanner (General Electric Medical Systems, Milwaukee, WI). \(^{11}\text{C}\)Erlotinib was injected as an i.v. bolus over 20 sec (injected radioactivity: 365 ± 20 MBq, corresponding to 5 ± 4 μg of unlabeled erlotinib). Radioactivity in the upper abdominal region was measured over 90 min by employing a consecutive frame sequence of 1 × 15, 3 × 5, 3 × 10, 2 × 30, 3 × 60, 2 × 150, and 16 × 300 sec. In parallel to PET imaging, serial blood samples were drawn from the radial artery for the first 2.5 min, followed by samples at 3.5, 5, 10, 20, 30, 40, 60, and 80 min after radiotracer injection. For both PET scans, subjects were asked to fast for at least 6 h before radiotracer injection. Approximately 3 h before the start of the second PET scan, an oral dose of 300 mg erlotinib (Tarceva, Roche Pharma, Nutley, NJ; two 150-mg tablets) was administered. Ten blood samples were collected at baseline and hourly for 8 h and at ~21 h after erlotinib intake. Blood samples were centrifuged to obtain plasma, which was kept at −80°C until analysis of erlotinib concentrations.

**Blood and metabolite analysis**

Aliquots of blood and plasma were measured for radioactivity in a gamma-counter, which was cross-calibrated with the PET camera. Selected plasma samples were analyzed for radiolabeled metabolites of \(^{11}\text{C}\)erlotinib (Supplementary Methods). Due to the low amount of radiolabeled metabolites in plasma, total radioactivity counts were used for construction of an arterial input function. Plasma protein binding of \(^{11}\text{C}\)erlotinib was determined by incubating a plasma sample obtained immediately before each PET scan with \(^{11}\text{C}\)erlotinib for 20 min at 37°C, followed by ultrafiltration using Microcon-10 kDa centrifugal filter units with an Ultracel-10 membrane (Millipore, Bedford, MA). The concentration of unlabeled erlotinib in plasma was determined by high-performance liquid chromatography with ultraviolet detection (Supplementary Methods). Pharmacokinetic parameters of erlotinib in plasma were determined with the Kinetica 2000 software package, v. 3.0 (InnaPhase).

**Imaging data analysis**

Regions of interest (ROIs) for liver, combined bile duct and gall bladder, left renal cortex and left colic flexure were manually delineated on individual MRI data coregistered to the respective PET data using PMOD...
3.6 (PMOD Technologies, Zurich, Switzerland). Radioactivity in the bile duct and gall bladder was assumed to correspond to radioactivity excreted into bile. Radioactivity concentrations in tissue (kBq/mL) were expressed as percent of the injected dose per mL (%ID/mL) or in case of bile duct and gall bladder as %ID by multiplication with the total ROI volume, see Supplementary Table 2) vs. time.

Modeling
Assuming that only the systemic blood, liver, bile duct, and gall bladder need to be considered as distribution organs, that excretion from bile does not occur during the PET study and that measured radioactivity in tissue corresponds to unmetabolized [11C]erlotinib, a compartment model for liver distribution was constructed (Figure 3). Hepatic tracer delivery via the portal vein was not considered in the model. The following differential equations were used:

\[
\begin{align*}
    V_d \frac{dC_{\text{blood}}}{dt} &= -k_{\text{backflux}} \times C_{\text{liver}} \times V_d - k_{\text{influx}} \times C_{\text{blood}} \\
    &\quad \times V_d - k_d \times C_{\text{blood}} \times V_d \\
    V_{\text{liver}} \frac{dC_{\text{liver}}}{dt} &= k_{\text{influx}} \times C_{\text{blood}} \times V_d - k_{\text{backflux}} \times C_{\text{liver}} \\
    &\quad \times V_{\text{liver}} - k_{\text{bile}} \times C_{\text{liver}} \times V_{\text{liver}} \\
    \frac{dX_{\text{bile}}}{dt} &= k_{\text{bile}} \times C_{\text{liver}} \times V_{\text{liver}}
\end{align*}
\]

where \( V_d \) and \( V_{\text{liver}} \) (mL) are the volume of distribution and physiological liver volume, respectively (Supplementary Table 3). \( C_{\text{blood}} \) and \( C_{\text{liver}} \) (kBq/mL) are the blood and liver concentrations of [11C]erlotinib, respectively. \( X_{\text{bile}} \) (kBq) is the total amount of [11C]erlotinib in bile duct and gall bladder. \( k_{\text{influx}}, k_{\text{backflux}} \), and \( k_{\text{bile}} \) (min\(^{-1}\)) are the rate constants for radiotracer transfer between blood, liver, and bile and \( k_d \) (min\(^{-1}\)) is the rate constant for elimination of [11C]erlotinib from bile (Figure 3). \( V_{\text{bile}} \) was estimated by fitting a two-compartment model to the blood concentration profiles of [11C]erlotinib. \( V_{\text{blood}} \) was calculated by a previously reported method. Blood concentration was obtained from \([11C]\)erlotinib plasma concentration and the plasma-to-blood concentration ratio. \( C_{\text{liver}} \) was calculated from the PET data using:

\[
C_{\text{liver}} = \frac{C_{\text{PET}} - 0.20 \times C_{\text{blood}}}{0.80}
\]

where \( C_{\text{PET}} \) is the liver concentration including the concentration in the vascular space in the liver. \( k_{\text{influx}}, k_{\text{backflux}}, k_{\text{bile}}, \) and \( k_d \) were estimated by fitting the data using the mutir program. Hepatic uptake clearance (\( CL_{\text{uptake}} \), mL min\(^{-1}\)) was calculated as \( k_{\text{influx}} \times V_d \).

Cell lines and in vitro uptake experiments
Different in vitro uptake experiments were performed with \([11C]\)erlotinib in human epidermal carcinoma A431 cells expressing different OATPs (OATP1B1, OATP1B3, or OATP2B1) and in A431 cells transfected with the empty vector, which had been generated as described elsewhere (Patik et al., submitted), as outlined in the Supplementary Methods.

Statistical analysis
All values are given as mean ± standard deviation (SD). Statistical testing was performed using Prism 6.0 software (GraphPad Software, San Diego, CA). Differences in outcome parameters between scans were tested using the Wilcoxon matched-pairs signed rank test. For analysis of in vitro data, differences between groups were analyzed by two-way analysis of variance followed by a Bonferroni posttest. The level of statistical significance was set to \( P \) value of less than 0.05.

Additional Supporting Information may be found in the online version of this article.

ACKNOWLEDGMENTS
This work was supported by the Austrian Science Fund (FWF) (grants KLI 480-B30, F 3513-B20 and F 3513-B25), by the Lower Austria Corporation for Research and Education (NFB) (grants LS12-006, LS15-003) and by the National Research, Development and Innovation Office (grant OTKA K 109423). Csilla Ozvegy-Laczka and Eva Bakos are recipients of the János Bolyai Scholarship of the Hungarian Academy of Sciences. The authors would like to thank study nurse Maria Weber (Department of Clinical Pharmacology) for her excellent support in this study. Moreover, Harald Ibeschitz and the other staff members of the PET center at the Division of Nuclear Medicine are acknowledged for their smooth cooperation in this study. The authors are grateful to Peter Marhofer and his team (Department of Anesthesia and Intensive Care Medicine, Medical University of Vienna) for their support in arterial cannulation of study participants and to Rudolf Karch (Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna) for helpful discussions. Oliver Langer, Marcus Hacker and Wolfgang Wadsak are members of the Medical Imaging Cluster (MIC) at the Medical University of Vienna.

CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest.

AUTHOR CONTRIBUTIONS
O.L., M.B., A.M., and G.S. wrote the article; O.L., M.B., A.M., C.Ö.-L., M.H., and M.Z. designed the research; M.B., B.W., C.P., A.T., L.N., E.-M.K., C.Ö.-L., J.S., P.I., E.B., and W.W. performed the research; M.B., A.M., A.T., C.Ö.-L., J.S., W.J., and O.L. analyzed the data; C.Ö.-L., I.P., E.B., and G.S. contributed new reagents/analytical tools.

© 2017 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

The copyright line for this article was changed on July 26, 2018 after original online publication.

1. Nies, A.T., Schwab, M. & Keppeler, D. Interplay of conjugating enzymes with OATP uptake transporters and ABC/MRP efflux pumps in the elimination of drugs. Expert Opin. Drug Metab. Toxicol. 4, 545–568 (2008).
2. Shitara, Y., Maeda, K., Ikejiri, K., Yoshida, K., Honie, T. & Sugiyama, Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm. Drug Dispos. 34, 45–78 (2013).
3. König, J., Seithel, A., Gradhand, U. & Fromm, M.F. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch. Pharmacol. 372, 432–443 (2006).
4. König, J., Müller, F. & Fromm, M.F. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol. Rev. 65, 944–966 (2013).
5. Maeda, K. & Sugiyama, Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab. Pharmacokinet. 23, 223–235 (2008).
6. Wang, L. et al. Transporter expression in liver tissue from subjects with alcoholic or hepatitis C cirrhosis quantified by targeted quantitative proteomics. Drug Metab. Dispos. 44, 1752–1758 (2016).
7. Wulkersdorfer, B., Wanek, T., Bauer, M., Zeitlinger, M., Müller, M. & Langer, O. Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues. Clin. Pharmacol. Ther. 96, 206–213 (2014).
8. Testa, A., Zanda, M., Elmore, C.S. & Sharma, P. PET tracers to study clinically relevant hepatic transporters. Mol. Pharm. 12, 2203–2216 (2015).
9. Langer, O. Use of PET imaging to evaluate transporter-mediated drug-drug interactions. J. Clin. Pharmacol. 56(Suppl 7), S143–S156 (2016).
10. Kusuhara, H. Imaging in the study of membrane transporters. Clin. Pharmacol. Ther. 94, 33–36 (2013).
11. Takashima, T. et al. PET imaging-based evaluation of hepatobiliary transport in humans with (15R)-[11C]-Ticlopidine. J. Nucl. Med. 53, 741–748 (2012).
12. Shingaki, T. et al. Evaluation of Oatp and Mrp2 activities in hepatobiliary excretion using newly developed positron emission tomography tracer [11C]dehydropravastatin in rats. J. Pharmacol. Exp. Ther. 347, 193–202 (2013).
13. He, J. et al. PET imaging of Oatp-mediated hepatobiliary transport of [11C]rosuvastatin in the rat. Mol. Pharm. 11, 2745–2754 (2014).
14. Takashima, T. et al. The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [11C]telmisartan. Mol. Pharm. 8, 1789–1798 (2011).
15. Omtøft, N.W., Munk, O.L., Frisch, K., Ott, P., Keiding, S. & Sørensen, M. Hepatobiliary transport kinetics of the conjugated bile acid tracer 11C-CSar quantified in healthy humans and patients by positron emission tomography. J. Hepatol. 67, 321–327 (2017).
16. Sundelin, E.I. et al. Genetic polymorphisms in organic cation transporter 1 attenuates hepatic metformin exposure in humans. Clin. Pharmacol. Ther. (2017) [Epub ahead of print].
17. Ling, J. et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab. Dispos. 34, 420–426 (2006).
18. Kodaira, H., Kusuhara, H., Ushiki, J., Fuse, E. & Sugiyama, Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J. Pharmacol. Exp. Ther. 333, 788–796 (2010).
19. Elmeliegy, M.A., Carcaboso, A.M., Tagen, M., Bai, F. & Stewart, C.F. Role of ATP-binding cassette and solute carrier transporters in erlotinib OGN penetration and intracellular accumulation. Clin. Cancer Res. 17, 89–99 (2011).
20. Troxil, A. et al. Breast cancer resistance protein and P-glycoprotein influence in vivo disposition of 11C-erlotinib. J. Nucl. Med. 56, 1930–1936 (2015).
21. Khurana, V., Minocha, M., Pal, D. & Mitra, A.K. Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. Drug Metab. Drug Interact. 29, 179–190 (2014).
22. Karigren, M. et al. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J. Med. Chem. 55, 4740–4763 (2012).
23. Johnston, R.A., Rawling, T., Chan, T., Zhou, F. & Murray, M. Selective inhibition of human solute carrier transporters by multikinase inhibitors. Drug Metab. Dispos. 42, 1851–1857 (2014).
24. Sato, T., Ito, H., Hirata, A., Abe, T., Mano, N. & Yamaguchi, H. Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3. Xenobiotica Jan 12, 1–6 (2017).
25. Ranson, M. et al. A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. Cancer Chemother. Pharmacol. 66, 53–58 (2010).
26. Murakami, T., Nakanishi, M., Yoshimori, T., Okamura, N., Norikura, R. & Mizojiri, K. Separate assessment of intestinal and hepatic first-pass effects using a rat model with double cannulation of the portal and jugular veins. Drug Metab. Pharmacokinet. 18, 252–260 (2003).
27. Davies, B. & Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093–1095 (1993).
28. Pfeifer, N.D. et al. Effect of ritonavir on (99m)technetium-mebrofenin disposition in humans: a semi-PBPK modeling and in vivo approach to predict transporter-mediated DDIs. CPT Pharmacometrics Syst. Pharmacol. 2, e20 (2013).
29. Gormsen, L.C. et al. In vivo imaging of human 11C-metformin in peripheral organs: dosimetry, biodistribution, and kinetic analyses. J. Nucl. Med. 57, 1920–1926 (2016).
30. Giacomini, K.M. et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215–236 (2010).
31. Kallikoski, A. & Niemi, M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158, 693–705 (2009).
32. Ho, R.H. et al. Drug and bile acid transporters in rosuvastatin hepatocellular uptake: function, expression, and pharmacogenetics. Gastroenterology 130, 1793–1806 (2006).
33. Goss, G.D. et al. A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. J. Transl. Med. 14, 83 (2016).
34. Bahce, I. et al. Development of [11C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status. Clin. Cancer Res. 19, 183–193 (2013).
35. Vauthey, J.N. et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 8, 233–240 (2002).
36. Sørensen, M. et al. Hepatobiliary secretion kinetics of conjugated bile acids measured in pigs by 11C-cholylsarcosine PET. J. Nucl. Med. 57, 961–966 (2016).
37. Yano, Y., Yamaoka, K. & Tanaka, H. A nonlinear least squares program, MULTI(FILT), based on fast inverse Laplace transform for microcomputers. Chem. Pharm. Bull. (Tokyo). 37, 1035–1038 (1989).